戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ce, ablation of Pml largely reduces IFNalpha angiostatic ability in Matrigel plug assays.
2  tumor growth in vivo and suggest that these angiostatic activities may one day be exploited to comba
3  that the WARS mutation could potentiate the angiostatic activities of TrpRS by enhancing its interac
4 ynthetase (T2-TrpRS) has demonstrated potent angiostatic activity during retinal developmental neovas
5                                          The angiostatic activity is dose-dependent in both systems.
6 ls may also use this receptor to mediate the angiostatic activity of IP-10/CXCL10, which is also expr
7                                To assess the angiostatic activity of T2-TrpRS, mice were injected int
8 ne, providing a possible explanation for the angiostatic activity of the peptide.
9 ran sulfate proteoglycan perlecan, possesses angiostatic activity via dual receptor antagonism, throu
10  IFNalpha-inducible effector, possess potent angiostatic activity, doing so in part by forming a posi
11                 T2-TrpRS demonstrated potent angiostatic activity, reducing the appearance of patholo
12 s in aberrant IFNalpha signaling and altered angiostatic activity.
13  the alpha2beta1 integrin and VEGFR2 for its angiostatic activity.
14 llin, the C-terminal module of perlecan, has angiostatic activity.
15 ran sulfate proteoglycan perlecan, possesses angiostatic activity.
16 ot been shown to bind CXCR3 receptor or have angiostatic activity.
17         This study examined the effect of an angiostatic agent on the growth of a highly vascularized
18            Calix[4]arene compound 0118 is an angiostatic agent that inhibits tumor growth in mice.
19 r treatment with anecortave acetate, a known angiostatic agent.
20 s was observed after treatment with a single angiostatic agent.
21 indings establish FBLN-3 and FBLN-5 as novel angiostatic agents capable of reducing tumor angiogenesi
22  of one of a variety of anti-inflammatory or angiostatic agents.
23  of thrombospondin-1 and TIMP3, two powerful angiostatic agents.
24 118 is a topomimetic of galectin-1-targeting angiostatic amphipathic peptide Anginex, we had yet to p
25 e characterized by up- and downregulation of angiostatic and angiogenic genes.
26                  The results identify direct angiostatic and antifibrotic effects of the Cxcr3 ligand
27 tained-release devices facilitate high local angiostatic and antipermeability concentrations while mi
28 , however, investigators have focused on the angiostatic and antipermeability properties of corticost
29 erived factor (PEDF) is a 50-kD protein with angiostatic and neurotrophic activities that regulates v
30                                     Both new angiostatic and traditional corticosteroids are currentl
31 accination-induced antisera displayed strong angiostatic and tumor-growth-inhibiting properties in a
32 ry genes; 3) late upregulated (days 7 to 14)-angiostatic, anti-inflammatory, and extracellular matrix
33 o suggest a heretofore unrecognized role for angiostatic basement membrane fragments in platelet biol
34 d on structure-activity relationships of the angiostatic beta-sheet-forming peptide anginex, we have
35                            Endorepellin, the angiostatic C-terminal domain of the heparan sulfate pro
36 r fibrosis by therapeutic treatment with the angiostatic chemokine Cxcl9 was systematically analyzed
37 mokines such as interleukin 8 (IL-8) and for angiostatic chemokines such as interferon-inducible prot
38                     IP-10 and MIG are potent angiostatic chemokines that may contribute to lung injur
39 ed a significant secretion of angiogenic and angiostatic chemokines, mainly across the hfRPE apical m
40                           Despite this, the 'angiostatic' chemokines inhibited the chemotactic respon
41 ncentrations (100-500 ng/ml) of each of the 'angiostatic' chemokines IP-10, ITAC, and MIG.
42 dent in part on a relative deficiency of the angiostatic CXC chemokine, IFN-gamma-inducible protein-1
43           These results demonstrate that the angiostatic CXC chemokine, IP-10, inhibits fibroplasia a
44  of liver scarring, but a functional role of angiostatic CXCR3 chemokines in this process is unclear.
45          Among inflammatory, angiogenic, and angiostatic cytokines and chemokines, only vascular endo
46                                          The angiostatic effect occurred despite high levels of vascu
47                                          The angiostatic effect of AxCAIL-13 was associated with down
48 t a promising new strategy to potentiate the angiostatic effect of endorepellin and perhaps other ang
49 her define the sequences responsible for the angiostatic effect of TSP-1, we used synthetic peptides.
50 tance against HTLV-induced tumors through an angiostatic effect.
51 ffects at low therapeutic concentrations but angiostatic effects at high concentrations that are reve
52  In addition, the MIG chemokine also induced angiostatic effects in the tumor vasculature.
53                         We conclude that the angiostatic effects of endorepellin in vivo are mediated
54               This knowledge of the specific angiostatic effects of IL-4 may help optimize target-ori
55 211377, but pronounced anti-inflammatory and angiostatic effects were achieved by adding the EP1 anta
56  reduces synovial tissue vascularization via angiostatic effects, mediates inhibition of angiogenesis
57                                              Angiostatic efficacy in the cornea is also observed when
58 osis can be attenuated by treatment with the angiostatic ELR(-) CXC chemokine, CXCL11.
59                                          The angiostatic ELR- chemokines were expressed at high level
60 creased expression of the interferon-induced angiostatic ELR- CXC chemokines is a feature of juvenile
61 tic repressor of multiple pro-angiogenic and angiostatic factor genes in cardiomyocytes.
62 mor-derived IP-10 is an important endogenous angiostatic factor in NSCLC.
63                 Here we identify Cxcl9 as an angiostatic factor secreted by osteoblasts in the bone m
64 ly described angiostatic factor, as a potent angiostatic factor that regulates non-small cell lung ca
65  now report that IP-10, a recently described angiostatic factor, as a potent angiostatic factor that
66 ht to determine the relationship of a potent angiostatic factor, endostatin (ES), with disease severi
67                         Endostatin, a potent angiostatic factor, was expressed in mouse muscle and se
68  Therefore, we hypothesized that circulating angiostatic factors could be linked to outcomes and repr
69 sity by exposure to different angiogenic and angiostatic factors demonstrated the utility of this sys
70 d concerted expression of pro-angiogenic and angiostatic factors needed to produce functional microva
71  Inhibition of angiogenesis by production of angiostatic factors should be a viable approach for canc
72 ilar natural proteolytic fragment are potent angiostatic factors that act through the vascular endoth
73 a dual and opposing system of angiogenic and angiostatic factors.
74  cytokine that also stimulates production of angiostatic factors.
75 for a novel downstream signaling axis for an angiostatic fragment and for the key components involved
76 ve identified a new role for this endogenous angiostatic fragment in inducing autophagy through a VEG
77  receptor antagonism could operate for other angiostatic fragments.
78  unraveled a mechanistic explanation for the angiostatic functions attributed to ADAMTS1 and demonstr
79 t Peg3 induced the secretion of the powerful angiostatic glycoprotein Thrombospondin 1 independently
80 microvessel density in vivo and generates an angiostatic>angiogenic tumor microenvironment that retar
81 ts in the expression of angiogenic (IL-8) vs angiostatic (IFN-gamma-inducible protein (IP-10)) CXC ch
82               Mini TrpRS is shown here to be angiostatic in a mammalian cell culture system, the chic
83 fic molecule designed as a substitute for an angiostatic inhibitory peptide.
84 which a subset of inflammatory cells secrete angiostatic ligands, which then contribute to a local at
85 tic effect of endorepellin and perhaps other angiostatic matrix proteins.
86 lar protein thrombospondin (TSP)-1, a potent angiostatic molecule and crucial activator of transformi
87 in, the C-terminal domain of perlecan, is an angiostatic molecule that acts as a potent inducer of au
88 se studies demonstrate synergism between two angiostatic molecules and that antiangiogenic therapy ca
89                       Therapies that combine angiostatic molecules targeting multiple, distinct aspec
90 demonstrate synergistic effects of combining angiostatic molecules that target distinct aspects of th
91   Tumor inhibition was presumably due to the angiostatic properties of anecortave acetate because the
92 ts ability to attract T cells as well as its angiostatic properties suggest that 6Ckine may be an eff
93                          M. miR-184 exhibits angiostatic properties via regulation of Akt and VEGF si
94 e other ligands of this receptor, 6Ckine has angiostatic properties.
95 tive kringle-containing fragments expressing angiostatic properties.
96 CXCL9) are T-cell chemoattractants that have angiostatic properties.
97  was inhibited when EPCs expressing a potent angiostatic protein were injected.
98 when compared with treatment with individual angiostatic protein.
99                      In the presence of both angiostatic proteins, endothelial cell proliferation was
100 bit VEGF-mediated angiogenesis and exert its angiostatic role in part via alphavbeta3 integrin.
101 epresents the first therapeutic effect of an angiostatic steroid in an animal model of neovascular re
102 tudy was designed to test the capacity of an angiostatic steroid, anecortave acetate, to inhibit reti
103            The inhibition of angiogenesis by angiostatic steroids has been demonstrated in a variety
104  the authors' laboratory have suggested that angiostatic steroids suppress the PA activity essential
105 w medical and surgical treatments, including angiostatic steroids, nonsteroidal inflammatory agents,
106                            Moreover, topical angiostatic strategies can lead to restoration of immune
107                                              Angiostatic therapies designed to inhibit neovasculariza
108 determine the efficacy of antiangiogenic and angiostatic therapy in targeting mature vessels in retin
109      In contrast, treatment with combination angiostatic therapy significantly reduced compensatory u
110 umor vascular obliteration using combination angiostatic therapy was associated with reduced tumor ma
111 ing pathway may thus enhance the efficacy of angiostatic treatments for cancer and neovascular eye di

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top